Cited by 258Attention Deficit Hyperactivity DisorderSchizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Emotional Dysregulation in Adult ADHD and Response to Atomoxetine

Reimherr, Frederick W., Marchant, Barrie K., Strong, Robert E., Hedges, Dawson W., Adler, Lenard, Spencer, Thomas J., West, Scott A., Soni, Poonam·2005·Biological Psychiatry

Abstract

Background Before 1980, attention-deficit/hyperactivity disorder (ADHD) was called minimal brain dysfunction and included emotional symptoms now listed as "associated features" in DSM-IV. Data from two multicenter, placebo-controlled studies with 536 patients were reexamined to assess: 1) the pervasiveness of these symptoms in samples of adults with ADHD; 2) the response of these symptoms to atomoxetine; and 3) their association with depressive/anxiety symptoms.Methods The Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) was used to assess temper, affective lability, and emotional overreactivity, thus identifying patients exhibiting "emotional dysregulation." Other DSM-IV Axis I diagnoses were exclusionary. Outcome measures were the Conners' Adult ADHD Rating Scale (CAARS) and the WRAADDS.Results Thirty-two percent of the sample met post hoc criteria for emotional dysregulation and had higher baseline scores on ADHD measures, a lower response to placebo, and greater response to atomoxetine (p = .048). Symptoms of emotional dysregulation had a treatment effect (p < .001) at least as large as the CAARS (p = .002) and the total WRAADDS (p = .001). Emotional dysregulation was present in the absence of anxiety or depressive diagnosis.Conclusions Symptoms of emotional dysregulation were present in many patients with ADHD and showed a treatment response similar to other ADHD symptoms.

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2005.04.040

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Among non-stimulant treatments, improvement of emotion regulation on atomoxetine paralleled improvement in core symptoms of ADHD among adults.

    “Among the non-stimulant treatments, improvement of emotion regulation on atomoxetine paralleled improvement in core symptoms of ADHD among adults (71).”
  • Recent clinic-based studies report impairing emotion dysregulation in between 34-70% of adults with ADHD, although population based studies are needed.

    “This has been supported to some extent by recent clinic-based studies reporting impairing emotion dysregulation in between 34-70% of adults with ADHD, although population based studies are needed (69-73)–Table 1.”
  • Atomoxetine may be indicated in patients with comorbid substance use disorders, emotional dysregulation or social anxiety.

    “Atomoxetine may be indicated in patients with comorbid substance use disorders, emotional dysregulation or social anxiety [295-297].”

Cites

Flagged first, then by citations

1 of the 30 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Reimherr, F. W., Marchant, B. K., Strong, R. E., Hedges, D. W., Adler, L., Spencer, T. J., West, S. A., & Soni, P.
Affiliations
  • University of Utah (US)
  • Brigham Young University (US)
  • New York University (US)
  • Harvard University (US)
  • CNS Healthcare (US)
Corresponding author
Reimherr, Frederick W.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2005-07
Volume
58
Issue
2
Pages
125-131
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2020006801
Cited by
258
References
30
Citations by year
2026: 8 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 12 · 2021: 10 · 2020: 6 · 2019: 11 · 2018: 12 · 2017: 17 · 2016: 14 · 2015: 17 · 2014: 22 · 2013: 16 · 2012: 15
FWCI
4.01
Type
journal article
Language
en
Open access
closed
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
adult ADHD, emotional dysregulation, atomoxetine, temper, emotional lability, treatment response, depressive symptoms, anxiety symptoms, Conners' Adult ADHD Rating Scale
MeSH terms
Atomoxetine Hydrochloride, Adult, Affective Symptoms, Analysis of Variance, Anxiety Disorders, Attention Deficit Disorder with Hyperactivity, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Norepinephrine, Propylamines, Adrenergic Uptake Inhibitors, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review